Humacyte is trading 5% down at $0.57 amid broader biotech weakness; no confirmed company-specific announcement was identified for September 1, 2026.
- XBI is down 4.24% during regular trading.
- The S&P 500 and Nasdaq are also lower as investors respond to geopolitical tensions, higher oil prices, Treasury yields, and cautious macroeconomic data.
- These factors are intensifying pressure on volatile biotechnology shares.